ArticleACS chemical biology2011
Bacterial self-resistance to the natural proteasome inhibitor salinosporamide A.
Article in ACS chemical biology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed.
- Mode of action guided metagenomic natural product discovery reveals convergent evolution of a ClpP-targeting motif.Nature communications · 2026Article
- ARTS-DB 2.0: an expanded database for target-directed genome mining across bacteria and fungi.Database : the journal of biological databases and curation · 2026Article
- Genomic analysis for the identification of bioactive compounds in Xenorhabdus stockiae strain RT25.5.Scientific reports · 2025Article
- Biosynthesis of rumbrins and inspiration for discovery of HIV inhibitors.Acta pharmaceutica Sinica. B · 2022Article
- Ψ-Footprinting approach for the identification of protein synthesis inhibitor producers.NAR genomics and bioinformatics · 2022Article
- Targeted Large-Scale Genome Mining and Candidate Prioritization for Natural Product Discovery.Marine drugs · 2022Review
- Production of Epoxyketone Peptide-Based Proteasome Inhibitors byFrontiers in microbiology · 2022Article
- Metabolomics and genomics in natural products research: complementary tools for targeting new chemical entities.Natural product reports · 2021Review
- Promising Activities of Marine Natural Products against Hematopoietic Malignancies.Biomedicines · 2021Review
- Chemical Elicitors Induce Rare Bioactive Secondary Metabolites in Deep-Sea Bacteria under Laboratory Conditions.Metabolites · 2021Article
- Phytoplankton trigger the production of cryptic metabolites in the marine actinobacterium Salinispora tropica.Microbial biotechnology · 2021Article
- Recent developments in self-resistance gene directed natural product discovery.Natural product reports · 2020Review
- Comparison of Antibiotic Resistance Mechanisms in Antibiotic-Producing and Pathogenic Bacteria.Molecules (Basel, Switzerland) · 2019Review
- Detecting and prioritizing biosynthetic gene clusters for bioactive compounds in bacteria and fungi.Applied microbiology and biotechnology · 2019Review
- Heterologous expression of a putative ClpC chaperone gene leads to induction of a host metabolite.Journal of the Brazilian Chemical Society · 2019Article
- Comparison of Strategies to Overcome Drug Resistance: Learning from Various Kingdoms.Molecules (Basel, Switzerland) · 2018Review
- (Immuno)proteasomes as therapeutic target in acute leukemia.Cancer metastasis reviews · 2017Review
- The Antibiotic Resistant Target Seeker (ARTS), an exploration engine for antibiotic cluster prioritization and novel drug target discovery.Nucleic acids research · 2017Article
- Phylogenomic Insight into Salinispora (Bacteria, Actinobacteria) Species Designations.Scientific reports · 2017Article
- Enzymatic Halogenation and Dehalogenation Reactions: Pervasive and Mechanistically Diverse.Chemical reviews · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Proteasome inhibitors have recently emerged as a therapeutic strategy in cancer chemotherapy, but susceptibility to drug resistance limits their efficacy. The marine actinobacterium Salinispora tropica produces salinosporamide A (NPI-0052, marizomib), a potent proteasome inhibitor and promising clinical agent in the treatment of multiple myeloma. Actinobacteria also possess 20S proteasome machinery, raising the question of self-resistance. We identified a redundant proteasome β-subunit, SalI, encoded within the salinosporamide biosynthetic gene cluster and biochemically characterized the SalI proteasome complex. The SalI β-subunit has an altered substrate specificity profile, 30-fold resistance to salinosporamide A, and cross-resistance to the FDA-approved proteasome inhibitor bortezomib. An A49V mutation in SalI correlates to clinical bortezomib resistance from a human proteasome β5-subunit A49T mutation, suggesting that intrinsic resistance to natural proteasome inhibitors may predict clinical outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.